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Summary Angiogenesis is an essential requirement for tumour growth and metastasis and is regulated by a complex network of factors
produced by both stromal cells and neoplastic cells within solid tumours. The cytokine tumour necrosis factor alpha (TNF-ca) and the enzyme
thymidine phosphorylase (TP) are two factors known to promote tumour angiogenesis. We have demonstrated recently that high numbers of
tumour-associated macrophages (TAMs) are significantly associated with increased tumour angiogenesis and poor prognosis in invasive
carcinoma of the breast. We have also shown that TAMs are a major source of TNF-a in invasive breast carcinomas, and that macrophage-
like stromal cells as well as tumour cells synthesize TP in such tumours. However, little is known of the factors that regulate the production or
activity of these factors in the tumour microenvironment. As TNF-a has been shown to up-regulate TP expression in tumour cells in vitro we
performed an immunohistochemical study to investigate the possibility that TNF-a may be involved in the regulation of TP expression by
malignant breast epithelial cells in vivo. To do this, we used a cocktail of non-neutralizing monoclonal anti-TNF-a antibodies to visualize both
TNF-a-expressing macrophages and TNF-a bound to its receptors on tumour cells and endothelial cells in a series of 93 invasive carcinomas
of the breast. A semiquantitative grading system was then used to compare these staining patterns with that for TP in the same biopsies.
TNF-a immunoreactivity was also compared with various important tumour variables known to relate to outcome in this disease (microvessel
density, node status, grade, stage, receptor status and macrophage infiltration), as well as relapse-free and overall survival data for these
patients. Our data show significant positive correlations between TNF-a bound to its receptors on tumour cells and: (1) TP protein production
by tumour cells, and (2) axillary lymph node status (i.e. metastasis). These results suggest that tumour cell responsiveness to TNF-a
produced by neighbouring TAMs may play a part in the regulation of TP expression by tumour cells as well as their metastatic behaviour. This
may explain, in part, the relationship between increased macrophage infiltration and angiogenesis in breast cancer, and further supports the
contention that TAMs may represent an important target for future anti-angiogenic therapies.
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Angiogenesis, the development of new blood vessels from an
existing vascular network, is an essential requirement for tumour
growth, and progression, and is regulated by a complex network of
cytokines, enzymes and adhesion molecules (Blood and Zetter,
1990). Recent studies have shown that macrophages, as well as
malignant cells, are an important source of such angiogenic factors
in solid tumours (Leek et al, 1994). This is supported by our recent
finding that high levels of tumour infiltration by macrophages is
associated with increased tumour angiogenesis and reduced survival
in ductal invasive carcinoma ofthe breast (Leek et al, 1996).
We and others have demonstrated recently that the cytokine
tumour necrosis factor alpha (TNF-a) and the intracellular enzyme
thymidine phosphorylase (TP) are two key angiogenic molecules
produced by focal areas of tumour-associated macrophages
(TAMs). In the case ofTNF-a, various techniques have been used
to visualize the production of TNF-ax mRNA (Miles,et al, 1994),
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intracellular TNF-a protein (Miles et al, 1994; Pusztai et al, 1994)
and secreted TNF-ax by TAMs in breast carcinoma (Lewis and
McGee, 1996). TP, on the other hand, is produced not only by
TAMs, but also by malignant epithelial cells and endothelial cells
in such malignant breast tissue (Fox et al, 1996; Relfet al, 1997).
In experimental systems, TNF-ax can both inhibit and stimulate
angiogenesis in a dose-dependent manner, with high doses in the 1
to 5-jig range being inhibitory, whereas low doses in the 0.01- to
1-ng range are stimulatory (Fajardo et al, 1992; Leek et al, 1994).
Moreover, we have shown that both forms ofTNF-x receptor (p55
and p75) are expressed by endothelial cells in such tissues, with
the smaller (p55) form of the TNF-ct receptor also expressed by
neoplastic cells and macrophage-like stromal cells, and the larger
(p75) variant by infiltrating stromal cells (Miles et al, 1994;
Pusztai et al, 1994). As it is unlikely that TNF-ax could reach the
high levels in the tumour microenvironment needed to be antian-
giogenic, and, as tumour angiogenesis and growth proceeds in the
presence ofTNF-ax in most tumours, it is likely that the net effect
ofthis cytokine on tumour angiogenesis tends towards stimulation
rather than inhibition.
*The first two authors contributed equally to this study.
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Table 1 Clinicopathological characteristics of patients and tumours
Patient characteristics Number
Age [median (range) years] 55 (28-83)
<50 36
.50 57
Surgical treatment
Lumpectomy + radiotherapy 77
Mastectomy 16
Adjuvant treatment
Chemotherapy 25
Tamoxifen 40
Lymph node status neg/pos 64/29
Tumour size [median (range) cm] 2.3 (1-7)
<2 36
>2 57
Histology
Ductal 75
Lobular 8
Mixed 7
Medullary 2
Mucinous 1
Grade
9
11 36
III 30
ERa [median (range)] 8.8 (0.695)
<10 49
.10 44
EGFRa [median (range)] 16 (0-710)
<20 53
>20 40
Survival follow-up [median (range)] 55 (6-92)
Deaths, recurrences 18, 29
afmol mg-1 protein. ER, oestrogen receptor; EGFR, epidermal growth factor
receptor
Thymidine phosphorylase, an enzyme originally isolated from
platelets and also known as platelet-derived endothelial cell
growth factor (PDECGF), catalyses the reversible phosphorolysis
of thymidine to deoxyribose 1-phosphate and thymine. TP has
been shown to exhibit a chemotactic and mitogenic capacity on
endothelial cells in several angiogenic model systems, and its
expression in human breast cancer cells has been shown to corre-
late with microvessel density in some studies (Fajardo et al, 1992;
Folkman, 1996; Fox et al, 1996). Moreover, TP expression is 260-
fold higher in invasive bladder cancer (O'Brien et al, 1995) and
27-fold higher in invasive breast carcinoma than normal tissue
(Patterson et al, 1995). In ovarian carcinomas, areas of increased
expression ofTP have been associated with high blood velocity as
measured by colour Doppler imaging (Reynolds et al, 1994).
In most normal organs, TP is most highly expressed in resident
tissue macrophages, and may be part of a mechanism controlling
angiogenesis in response to injury (Fox et al, 1995a). TP is not a
classic type of pro-angiogenic factor in tumours as it is thought to
exert its angiogenic effects via the metabolites of its enzymatic
activity (Moghaddam and Bicknell, 1992). DNAreleased from dying
cells and engulfed in apoptotic nuclei may be degraded to thymidine,
which can freely enter cells, including tumour cells and TAMs,
which then metabolize thymidine via TP to angiogenically active
metabolites such as deoxyribose-1-phosphate. TP also catalyses the
phosphorolytic cleavage ofthe chemotherapeutic pro-drug 5'-deoxy-
5-fluorouridine (5'-DFUR) to its therapeutically active form 5-fluo-
rouracil (5-FU) (Patterson et al, 1995), and it is thought that
resistance to 5'-DFURtherapy maybedue to lowTPactivity in some
tumours.
As TNF-ca has been shown to up-regulate markedly TP activity
in tumour cell lines in vitro (Eda et al, 1993), the purpose of this
study was to investigate whether TNF-a may be involved in the
regulation ofTP in vivo. To do this, we used non-neutralizing anti-
bodies for TNF-x that recognize both unbound and receptor-bound
TNF-ax to correlate the cellular distribution ofTNF-a protein (both
TNF-a expression by TAMs and TNF-a bound to receptors on
tumour and endothelial cells) with that ofTP protein expression by
tumour cells in a consecutive series of primary invasive human
breast carcinomas. We also correlated the cellular distribution of
TNF-ax with a range ofimportant tumour variables in breast cancer,
such as angiogenesis, receptor status, axillary lymph node involve-
ment, focal macrophage infiltration and prognosis.
MATERIALS AND METHODS
Patients and tissues
A consecutive series of 93 surgically resected invasive breast
carcinomas was retrieved from the archives of the John Radcliffe
Hospital, Oxford. All had axillary node sampling, and the presence
of nodal metastasis was confirmed histologically. The modified
Bloom and Richardson method was used to grade all invasive
carcinomas ofductal type, and all patients were followed-up every
3 months for the first 18 months and every 6 months thereafter.
The characteristics ofthis series oftumours are detailed in Table 1.
All patients received either simple mastectomy or lumpectomy
and radiotherapy. Adjuvant radiotherapy was administered to the
ipsilateral axilla if histological evidence of nodal metastasis was
found. Patients with confirmed recurrent disease were treated by
endocrine manipulation for soft tissue or skeletal disease or by
chemotherapy for visceral disease or failed endocrine therapy.
Patients with isolated soft tissue relapse received radiotherapy.
Details of adjuvant treatment consisting of tamoxifen for 5 years
and cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
intravenously for six courses are shown in Table 1.
Immunohistochemistry
Immunohistochemical staining for TNF-a and TP was performed
on separate formalin-fixed paraffin-embedded, 5-gm serial
sections cut on to coated slides. For TNF-a staining a cocktail of
monoclonal antibodies was used comprising equal proportions of
clone 4C6-C2 neat supernatant (kindly donated by P Balough,
University Medical School of Pecs, Hungary), characterized by
binding and competitive enzyme-linked immunosorbent assay
(ELISA) using synthetic and recombinant antigens (Bebok et al,
1994), and clones 6/10 and 6/35 supematants diluted 1:10 in tris-
buffered saline (kindly donated by A Meager, NIBSC, Potters Bar,
UK), screened by solution-phase immunoprecipitation (Meager et
al, 1987). The sections were visualized using a standard indirect
peroxidase technique and the chromogen 3-amino-9-ethyl-
carbazole (AEC), yielding a brownish red reaction product. As a
negative control, to confirm specificity of staining, mouse mono-
clonal anti-rabbit IgG was substituted for the primary antibody at
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A method using 3,3'-diaminobenzidine tetrachloride (DAB) as the
"N 0", ~~~~~~~chromogen yielding a brown reaction product was used to
W x, ' visualize TP staining.
Assessment of TNF-c and TP expression
TNF-a expression was assessed by two observers simultaneously
using a conference microscope. The malignant epithelial cell
population, tumour endothelium and TAMs were assessed sepa-
rately across the whole slide. Tumour cells were graded by the
overall percentage of malignant cells stained positive (0, 0% posi-
tive; 1, <25% positive, 2, 25-75% positive; and 3 >75% positive).
Endothelial cell staining was assessed simply for the presence or
absence of staining and TAM staining was graded according to the
number of macrophage hotspots defined as the number of high-
power fields (x400 magnification) containing >75% of
B macrophages with positive staining (0, negative; 1, occasional
~~~ w ~~~~~positive TAM; 2, < five TAM hotspots; and 3, > five TAM
& 3., N hotspots). TP staining in the malignant tumour epithelium was
;^. i= graded in the same way as described above for TNF-oc. Tumours
were considered TP positive if more than 25% of the tumour cells
~ ~~~~~~. ...... displayed moderate staining, as this cut point has previously been
found to be significant in predicting survival in node-positive
~~~ ~~breast tumours treated with CMF, with high TP expressers
showing improved survival (Fox et al, 1996).
ER and EGFR
Oestrogen receptor (ER) analysis was performed using an ELISA
i >fi->;;i technique (Abbott Laboratories, USA). Tumours with cytoplasmic
oestrogen levels higher than 5 fmol mg- protein were considered
\".$> 4; positive. Epidermal growth factor receptor (EGFR) was deter
mined using ligand binding of ['211]EGF to tumour membranes.
C Tumours with an EGFR level of greater than 20 fmol mg-' protein
}K7`*i w considered positive (Nicholson et al, 1988).
Vascular grade and macrophage index
* ) /t1 Chalkley vascular count (CVC) and macrophage index (M01)
were determined quantitatively using Chalkley point array
-*W counting methodologies described previously (Fox et al 1995b;
Leek et al 1996).
wt 'Ali Statistical analysis
4- P Jk. Chi-square and Fisher's exact tests were used to investigate
> ,-S,-t *~ |a__u_\ i<i :>4t
W relationships between categorical tumour variables, and
1w 94i, w < \ vMann-Whitney non-parametric tests were used to compare cate-
^; *Mt * * gorical with continuous tumour variables. These analyses were
tl* t o__** p 9 *!*i performed using Statview 4.5 statistical analysis software (Abacus
concepts, Berkeley, CA, USA). Survival analysis was performed
Figure 1 TNF-ai immunohistochemistry of breast carcinoma. Arrows using the log-rank test to evaluate differences between life tables.
indicate areas of staining, scale bar = 100 gm. A, Intense cytoplasmic
staining of an island of invasive neoplastic cells. B, Positive staining of Survival analyses were accomplished using Stata release 3.1 soft-
tumour-infiltrating macrophages. C, Positive staining oftumour-associated ware (Stata, College Station, TX, USA).
blood vessels
RESULTS
the same IgG concentration. The monoclonal antibody PG44c was
used to stain for TP on a separate section. This antibody has previ-
ously been characterized using Western blot analysis and immuno- A proportion of neoplastic tumour cells were positive for TNF-x
cytochemistry on TP transfected MCF-7 cells (Fox et al, 1995). in 97% ofall the cases examined (Figure IA). A total of36% ofall
A standard peroxidase streptavidin-biotin complex (ABC) cases were classified as TNF-ax grade 1, with 59% scoring 2 and
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Table 2 TNF-a immunohistochemistry results. No association between
TNF-alpha expression in TAMs vs neoplastic cells (A) or vessels (B); neither
is there an association between vessel and neoplastic cell staining (C). An
association was seen between TNF-oc and TP expression in the neoplastic
cell population (D)
(A) TNF-a staining (B) TNF-a staining
Neoplastic cells Vessels
U) + cases - cases + cases - cases
+ 25 32 + 27 9
- 11 21 - 31 20
(P= 0.5) (P= 0.25)
(C) TNF-a staining U (D) TP staining
Neoplastic cells CD Neoplastic cells
CD + cases - cases .o + cases - cases
a, + 40 18 U + 30 10
-16 13 '-- 18 18
(P= 0.3) z (P= 0.03)
2% scoring 3. For comparison with other tumour variables TNF-a
grade 1 was considered low and grades 2 and 3 high. A subset of
the total TAM population in these tumours was found to be posi-
tive for TNF-a in 93% of all cases (Figure 1B). Tumours with
TNF-a staining ofTAMs with grade 0 and 1 were considered low
expressers, whereas those with grades 2 and 3 were classified as
high expressers. A subset of the total vascular endothelial cell
population was also immunoreactive for TNF-a in 67% of
tumours (Figure IC). No relationship was observed between high
TNF-a expression by TAMs compared with either neoplastic (chi-
square 0.43, P = 0.51, Fisher's exact P value = 0.5) (Table 2A) or
endothelial cell staining (chi-square 1.34, P = 0.25, Fisher's exact
P value = 0.25) (Table 2B). Neither was any relationship observed
between vessel and high neoplastic cell staining (chi-square 1.06,
P = 0.3, Fisher's exact P value = 0.2) (Table 2C).
Relationship of TP to TNF-oc expression
TP expression was confirmed in 53% oftumours examined. When
TP expression was compared with TNF-ax expression, a positive
association was observed between high TP expression and high
TNF-a immunoreactivity for the neoplastic cell population (chi-
square 4.07, P = 0.04, Fisher's exact P value = 0.03) (Table 2D),
with no significant associations between TP expression and TNF-
oc immunoreactivity for TAMs or endothelial cells.
Relationship of TNF-a protein to clinicopathological
tumour variables
The TNF-oc immunoreactivity ofneoplastic cells, endothelial cells
and TAMs was compared with tumour variables known to relate to
outcome. They included node status, tumour size at excision,
patient age, histological type, grade, ER expression and EGFR
expression. A positive association was noted between high TNF-ac
immunoreactivity for the neoplastic cell population and node
involvement (chi-square 3.4, P = 0.06, Fisher's exact P value =
0.05), and an association with larger tumour size and TNF-ax
vessel positivity was also seen where size was tested as a contin-
uous variable (Mann-Whitney U, P = 0.03).
Relationship of TNF-a protein to vascular count and
macrophage index
No associations were observed between vascular count and TNF-a
positivity for TAMs, neoplastic or endothelial cells. When
compared with macrophage index, no associations were found
with high TNF-a expression in neoplastic or endothelial cells.
However, an association was observed between higher
macrophage index and increased numbers of TNF-a-expressing
TAMs (Mann-Whitney U, P = 0.05).
Relationship of TP protein to clinicopathological
tumour variables
No associations were found between TP staining and the prog-
nostic features of age, tumour size, tumour histology, grade, node
status, ER and EGFR. Neither was an association found with
vascular count or relapse-free and overall survival.
TNF-a protein and prognosis
No effect on relapse-free survival (RFS) or overall survival (OS)
was observed for TNF-a positivity in either the neoplastic (RFS P
= 0.12, OS P = 0.64), endothelial (RFS P = 0.22, OS P = 0.58) or
TAM cell populations (RFS P = 0.28, OS P = 0.71).
DISCUSSION
In this report we have attempted to visualize total TNF-a (i.e.
intracellular protein in producer cells and receptor-bound protein
on target cells) in a series of invasive breast carcinomas, and to
correlate this not only with tumour cell production of the pro-
angiogenic enzyme TP, but also various other parameters of
tumour growth and spread such as angiogenesis, axillary lymph
node status and hormone receptor expression.
Using a cocktail of well-characterized, non-neutralizing mono-
clonal antibodies for TNF-a, we found an abundance of this
cytokine in malignant breast tissue, with immunoreactivity
demonstrated by TAMs, malignant epithelial cells and vascular
endothelial cells in the majority of tumours studied. In light of
previous studies showing TAMs to be the only major source of
TNF-a in breast carcinoma (Miles et al, 1994; Pusztai et al, 1994;
Lewis and McGee, 1996), we have interpreted ourTNF-a staining
patterns to indicate the presence of TNF a-producing TAMs as
well as TNF-a bound to receptors on malignant cells and tumour
endothelium. Although the present study also revealed a signifi-
cant correlation between high levels of macrophage density and
increased numbers of TNF-a expressing TAMs (93% of all cases
showing some TNF-a-positive TAMs), only a subpopulation of
TAMs (usually an isolated cluster of cells) was seen to actually
produce TNF-oc. This finding confirms those of earlier studies
(Miles et al, 1994; Pusztai et al, 1994) showing that TAM produc-
tion of TNF-a occurs predominantly in 'hotspots' in malignant
breast tissue, where tumour microenvironmental factors at certain
tumour sites are thought to cause macrophages to cluster and
manufacture this cytokine. Indeed, such macrophage clustering
may regulate both TNF-a production and/or its effects on target
cells in tumours. We recently demonstrated that TAMs congregate
at highest density in relatively avascular, hypoxic sites in breast
carcinomas (Leek et al, 1996). The very low levels of oxygen
present in such tumour areas have been shown to regulate both the
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expression of TNF-oc and its receptors by macrophages in vitro
(Scannell et al, 1993), as well as the cytotoxic effects ofTNF-X on
its target cells (Lewis and Balkwill, 1997). It is possible that the
TNF-oc hotspots recorded here and elsewhere (Miles et al, 1994;
Pusztai et al, 1994; Lewis and McGee, 1996) may be a product, in
part, of tumour hypoxia in these regions. Hypoxia may also
influence the effect of this cytokine on tumour angiogenesis by
modifying the expression and post-receptor loci of TNF-oc recep-
tors. In this respect it is interesting to note that hypoxia has been
shown to modify the expression of TNF-ox p75 receptors in vitro
(D Maennel and G Grau, unpublished observations).
This present study did not, however, find any relationship
between either TAM production of TNF-oc or TNF-ct bound to
endothelial cells and vascular grade (i.e. angiogenesis).
Angiogenesis is thought to be regulated by a large network of
inter-relating factors rather than one factor alone (Leek et al, 1994;
Folkman, 1996). The presence, however, of receptor-bound TNF-
1x on the tumour endothelium of 66% of cases does indicate that
TNF-oc may be an element in the complex regulation of angio-
genesis. This is also supported by the observation that there is an
association between increased vessel staining and larger tumour
size. Increased angiogenesis is a requirement for tumour growth
and may be particularly important in larger tumours where diffu-
sion distances are greater.
That increased TP expression was seen in this study to be associ-
ated with increased TNF-oc immunoreactivity ofthe malignant cell
population of breast carcinomas strongly suggests that malignant
breast epithelial cells may be a target cell population for TAM-
derived TNF-cx, and that they may up-regulate TP in response to
this cytokine. This may account for the relationship between
tumour macrophage infiltration and angiogenesis, and this pathway
may be an important component in the overall network of factors
regulating angiogenesis in breast carcinoma. However, it is note-
worthy that there was no significant association of TP with angio-
genesis in this study, although earlier studies reported a positive
correlation in this disease. Nor did TP correlate with other clinical
and pathological variables. The reason for the discrepancy is
unclear but may indicate the importance of multiple factors in the
regulation of tumour angiogenesis, and the complexity of cellular
interactions and cytokine networks with multiply redundant path-
ways that influence tumour progression. Indeed, we have recently
shown the presence ofat least six vascular growth factors in malig-
nant breast tumours (Relfet al, 1997).
Our finding that increased TNF-ax staining of tumour cells was
correlated with the presence ofnodal metastases accords well with
previous reports showing the enhanced metastatic potential of
tumour cells in vivo, following exposure to TNF-ox (Malik et al,
1990; Orosz et al, 1993). Moreover, TNF-ox is known to induce
expression of adhesion molecules thought to be involved in the
increased motility and invasive/metastatic behaviour of tumour
cells (loculano et al, 1995). However, no association between
TNF-oc immunoreactivity of any cell type and poor survival was
evident in this study, possibly indicating that, although TNF-oc
could be involved in regulating nodal metastasis and an important
element of the metastatic pathway, its effects are not sufficiently
independent to affect prognosis directly.
In conclusion, the relationship between TNF-oc protein expres-
sion and angiogenesis and tumour progression is complex. It may
be able to stimulate angiogenesis directly by its actions on
endothelial cells, and importantly it may also affect angiogenesis
indirectly by its ability to modulate expression of other factors
such as TP, which appears to be up-regulated in breast cancer. The
involvement ofTNF-a in these processes, and its association with
TP expression in particular, also underlines the importance of the
TAM population, in breast cancer, as the most likely source ofthis
cytokine, and may account in part for the strong association of
focal macrophage infiltration with increased angiogenesis and
reduced survival described earlier. It also reinforces the concept of
TAMs as therapeutic targets for future anti-cancer and anti-
angiogenic therapies. This could be achieved in a number ofways;
for example, it may be desirable to further up-regulate TP using
TNF-ct therapy in order to render the tumour more sensitive to 5-
FU. Alternatively, drugs such as vesnarinone (Kambayashi et al,
1996) could be used to inhibit TNF-ox production in the
TAM population, thus reducing the angiogenic or pro-metastatic
stimulus provided by this cytokine.
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